[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"article-how-digital-heart-twins-guided-successful-vt-ablation-in-10-patients-en":3,"ArticleBody_eBxDhLXKU2ANyBIfEPFTZGE1dTKn627MgMjsD3jO7VA":175},{"article":4,"relatedArticles":167,"locale":65},{"id":5,"title":6,"slug":7,"content":8,"htmlContent":9,"excerpt":10,"category":11,"tags":12,"metaDescription":10,"wordCount":13,"readingTime":14,"publishedAt":15,"sources":16,"sourceCoverage":57,"transparency":59,"seo":62,"language":65,"featuredImage":66,"featuredImageCredit":67,"isFreeGeneration":71,"niche":72,"geoTakeaways":76,"geoFaq":85,"entities":95},"69d48127fc9a83011893c2c3","How Digital Heart Twins Guided Successful VT Ablation in 10 Patients","how-digital-heart-twins-guided-successful-vt-ablation-in-10-patients","## From Ventricular Tachycardia to Digital Heart Twins: Why This Trial Matters\n\n[Ventricular tachycardia](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FVentricular_tachycardia) (VT) is a rapid rhythm from the heart’s lower chambers that can degenerate into ventricular fibrillation and sudden cardiac arrest, contributing to roughly 300,000 deaths per year in the United States. [5] It is especially common after myocardial infarction, where scar tissue creates the substrate for re‑entrant electrical circuits. [6]\n\n[Catheter ablation](https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FCatheter_ablation)—threading catheters into the heart to burn small areas of tissue—is standard therapy for drug‑refractory VT. [2] It is technically demanding, as operators must reconstruct complex arrhythmia circuits inside a scarred ventricle, often over many hours under general anesthesia. [6] Even in expert centers, VT recurs in about 40% of patients after conventional ablation, underscoring how hard it is to identify all critical pathways. [2][6]\n\n- VT ablation is effective but imprecise.  \n- Recurrence remains high despite advanced mapping. [2][6]\n\nMedical digital twins offer a potential upgrade. These patient‑specific computer models replicate organ anatomy and behavior so clinicians can test virtual interventions before treating the patient. [7][8] In cardiology, a digital heart twin uses imaging and physiologic data to predict how electrical waves propagate, where they short‑circuit, and how ablation could interrupt these circuits. [7]\n\nFor VT, cardiac digital twins typically:  \n\n- Use contrast‑enhanced cardiac MRI to reconstruct 3D ventricular anatomy and distinguish dense scar, border zones, and healthy myocardium. [3][6]  \n- Assign different electrical properties to each tissue type and simulate activation spread.  \n- Apply pacing protocols to provoke re‑entrant VT and expose potential isthmuses and ablation targets that may be elusive in the lab. [3][4][7]\n\nThe TWIN‑VT trial is one of the first FDA‑approved clinical studies to use such digital twins prospectively to guide human VT ablation. [1][4] Ten patients with prior myocardial infarction and recurrent VT underwent MRI‑based modeling; their ablation strategies were then planned around targets predicted by their virtual hearts. [1][2][4]\n\n⚠️ **Key point:** TWIN‑VT shifts digital heart twins from concept to real‑time decision support in a high‑risk VT population. [1][4]\n\n---\n\n## Inside the 10‑Patient TWIN‑VT Study: Design, Workflow, and Outcomes\n\nTWIN‑VT was a single‑center, FDA‑approved investigational device study enrolling 10 patients with post‑infarct VT at high risk for recurrence. [1][2] Each participant underwent:\n\n- Pre‑procedural contrast‑enhanced cardiac MRI  \n- Construction of an individualized ventricular twin  \n- In‑silico testing of ablation strategies  \n- Catheter ablation guided by modeled targets [1][3][4][6]\n\nIn the virtual workflow, clinicians “paced” each digital heart to trigger VT and observed how wavefronts interacted with scar and border zones. [3][4] Areas where wavefronts became trapped or repeatedly re‑entered were flagged as critical components of the arrhythmia circuit. Investigators then iteratively tested different virtual ablation lines until VT was fully suppressed in simulation. [3][4][5]\n\nThe workflow below summarizes how digital heart twins were used in TWIN‑VT, from imaging to final ablation in the EP lab. [1][2][3][4][6]\n\n```mermaid\nflowchart LR\n    title Digital Heart Twin-Guided VT Ablation Workflow\n    A[Post-infarct VT] --> B[Cardiac MRI]\n    B --> C[Build twin]\n    C --> D[In-silico pacing]\n    D --> E[Test lesion sets]\n    E --> F[Select plan]\n    F --> G[Map integration]\n    G --> H[Twin-guided ablation]\n\n    classDef info fill:#3b82f6,color:#ffffff,stroke:#1d4ed8;\n    classDef warning fill:#f59e0b,color:#000000,stroke:#b45309;\n    classDef success fill:#22c55e,color:#000000,stroke:#16a34a;\n\n    class B,C,D info;\n    class E,F warning;\n    class H success;\n```\n\nA case example from TWIN‑VT illustrates this: the digital twin exposed a narrow isthmus buried deep within heterogeneous scar that conventional mapping had missed, allowing operators to focus energy on that corridor rather than ablating broad myocardial areas. [3][6]\n\n📊 **Data highlight:** Digital‑twin–guided planning let clinicians test multiple lesion sets virtually and select the one most likely to terminate VT before entering the lab. [3][4]\n\nTo implement this plan, model‑derived targets were integrated with clinical mapping systems, overlaying “heat maps” of critical pathways onto fluoroscopy and 3D maps. [2][3] Operators then concentrated radiofrequency energy on predicted isthmuses while sparing healthy tissue, aiming for safer, shorter, and more focused procedures. [2][4][6]\n\nOutcomes:\n\n- VT noninducible at procedure end in all 10 patients (100% acute success). [1][2][3]  \n- No periprocedural complications reported. [1][2][3]  \n- Over ≈13‑month follow‑up, 8\u002F10 remained free of recurrent VT without antiarrhythmic drugs; 2 had early recurrences controllable with medication. [1][2][6]  \n- Historical recurrence rates near 40% after standard ablation make these outcomes encouraging, though direct comparative trials are lacking. [2][6]\n\n💡 **Key takeaway:** In this feasibility study, every patient achieved acute VT suppression, and most remained arrhythmia‑free at one year without antiarrhythmic drugs. [1][2]\n\n---\n\n## Implications, Limitations, and the Future of Digital Heart Twins in Electrophysiology\n\nClinically, a 100% acute success rate and high arrhythmia‑free survival suggest that digital twin–guided ablation may:\n\n- Produce more targeted lesion sets  \n- Reduce unnecessary myocardial damage  \n- Potentially shorten procedure and fluoroscopy times  \n- Lower the need for repeat procedures and shocks in patients with implantable defibrillators [2][3][4][6]\n\nDigital twins also align with the broader vision of precision cardiology. Validated virtual organs can integrate structural imaging, ECG data, device telemetry, and eventually genomics to support individualized risk prediction and therapy planning. [7][8] As new data are added, the twin could evolve with the patient, enabling dynamic forecasts of disease trajectory and treatment response. [7]\n\nYet major caveats remain:\n\n- Only 10 patients, single‑center, no randomized control arm. [1][2][5]  \n- Limited generalizability and no proof of superiority, cost‑effectiveness, or long‑term durability. [2][6]  \n- Need for high‑quality MRI, modeling expertise, and robust integration with mapping systems. [3][6][7]  \n- Regulatory requirements for verification, validation, and uncertainty quantification are still evolving. [7][8]\n\nLooking ahead, cardiac digital twins may extend beyond VT to atrial fibrillation, heart failure device optimization, and structural interventions such as valve repair. [7][8] Combining mechanistic models with artificial intelligence could accelerate simulation and refine parameter estimation from routine clinical data, supporting longitudinal “lifelong” heart twins across a patient’s care journey. [7][8]\n\n⚠️ **Key point:** For now, digital twins should be viewed as an investigational adjunct, not a replacement for guideline‑directed care; clinical judgment remains central. [2][7]\n\n---\n\n## Conclusion: What TWIN‑VT Signals for Personalized VT Care\n\nIn the FDA‑approved TWIN‑VT feasibility trial, patient‑specific digital heart twins successfully guided ablation in 10 high‑risk patients with post‑infarct VT, achieving 100% acute noninducibility and encouraging one‑year arrhythmia‑free survival without antiarrhythmic drugs in most participants. [1][2] The study illustrates how mechanistic simulations can sharpen precision in electrophysiology while highlighting the need for larger trials to confirm benefit, durability, and value. [2][6][7]\n\nClinicians, health‑system leaders, and researchers should follow forthcoming multicenter studies and consider structured pilot collaborations with modeling teams as evidence matures, integrating digital twins thoughtfully alongside established VT care pathways. [1][2][6][7]","\u003Ch2>From Ventricular Tachycardia to Digital Heart Twins: Why This Trial Matters\u003C\u002Fh2>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FVentricular_tachycardia\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">Ventricular tachycardia\u003C\u002Fa> (VT) is a rapid rhythm from the heart’s lower chambers that can degenerate into ventricular fibrillation and sudden cardiac arrest, contributing to roughly 300,000 deaths per year in the United States. \u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa> It is especially common after myocardial infarction, where scar tissue creates the substrate for re‑entrant electrical circuits. \u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>\u003Ca href=\"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FCatheter_ablation\" class=\"wiki-link\" target=\"_blank\" rel=\"noopener\">Catheter ablation\u003C\u002Fa>—threading catheters into the heart to burn small areas of tissue—is standard therapy for drug‑refractory VT. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa> It is technically demanding, as operators must reconstruct complex arrhythmia circuits inside a scarred ventricle, often over many hours under general anesthesia. \u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa> Even in expert centers, VT recurs in about 40% of patients after conventional ablation, underscoring how hard it is to identify all critical pathways. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cul>\n\u003Cli>VT ablation is effective but imprecise.\u003C\u002Fli>\n\u003Cli>Recurrence remains high despite advanced mapping. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Medical digital twins offer a potential upgrade. These patient‑specific computer models replicate organ anatomy and behavior so clinicians can test virtual interventions before treating the patient. \u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003Ca href=\"#source-8\" class=\"citation-link\" title=\"View source [8]\">[8]\u003C\u002Fa> In cardiology, a digital heart twin uses imaging and physiologic data to predict how electrical waves propagate, where they short‑circuit, and how ablation could interrupt these circuits. \u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>For VT, cardiac digital twins typically:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Use contrast‑enhanced cardiac MRI to reconstruct 3D ventricular anatomy and distinguish dense scar, border zones, and healthy myocardium. \u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Assign different electrical properties to each tissue type and simulate activation spread.\u003C\u002Fli>\n\u003Cli>Apply pacing protocols to provoke re‑entrant VT and expose potential isthmuses and ablation targets that may be elusive in the lab. \u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>The TWIN‑VT trial is one of the first FDA‑approved clinical studies to use such digital twins prospectively to guide human VT ablation. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa> Ten patients with prior myocardial infarction and recurrent VT underwent MRI‑based modeling; their ablation strategies were then planned around targets predicted by their virtual hearts. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>⚠️ \u003Cstrong>Key point:\u003C\u002Fstrong> TWIN‑VT shifts digital heart twins from concept to real‑time decision support in a high‑risk VT population. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Chr>\n\u003Ch2>Inside the 10‑Patient TWIN‑VT Study: Design, Workflow, and Outcomes\u003C\u002Fh2>\n\u003Cp>TWIN‑VT was a single‑center, FDA‑approved investigational device study enrolling 10 patients with post‑infarct VT at high risk for recurrence. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa> Each participant underwent:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Pre‑procedural contrast‑enhanced cardiac MRI\u003C\u002Fli>\n\u003Cli>Construction of an individualized ventricular twin\u003C\u002Fli>\n\u003Cli>In‑silico testing of ablation strategies\u003C\u002Fli>\n\u003Cli>Catheter ablation guided by modeled targets \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>In the virtual workflow, clinicians “paced” each digital heart to trigger VT and observed how wavefronts interacted with scar and border zones. \u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa> Areas where wavefronts became trapped or repeatedly re‑entered were flagged as critical components of the arrhythmia circuit. Investigators then iteratively tested different virtual ablation lines until VT was fully suppressed in simulation. \u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>The workflow below summarizes how digital heart twins were used in TWIN‑VT, from imaging to final ablation in the EP lab. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cpre>\u003Ccode class=\"language-mermaid\">flowchart LR\n    title Digital Heart Twin-Guided VT Ablation Workflow\n    A[Post-infarct VT] --> B[Cardiac MRI]\n    B --> C[Build twin]\n    C --> D[In-silico pacing]\n    D --> E[Test lesion sets]\n    E --> F[Select plan]\n    F --> G[Map integration]\n    G --> H[Twin-guided ablation]\n\n    classDef info fill:#3b82f6,color:#ffffff,stroke:#1d4ed8;\n    classDef warning fill:#f59e0b,color:#000000,stroke:#b45309;\n    classDef success fill:#22c55e,color:#000000,stroke:#16a34a;\n\n    class B,C,D info;\n    class E,F warning;\n    class H success;\n\u003C\u002Fcode>\u003C\u002Fpre>\n\u003Cp>A case example from TWIN‑VT illustrates this: the digital twin exposed a narrow isthmus buried deep within heterogeneous scar that conventional mapping had missed, allowing operators to focus energy on that corridor rather than ablating broad myocardial areas. \u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>📊 \u003Cstrong>Data highlight:\u003C\u002Fstrong> Digital‑twin–guided planning let clinicians test multiple lesion sets virtually and select the one most likely to terminate VT before entering the lab. \u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>To implement this plan, model‑derived targets were integrated with clinical mapping systems, overlaying “heat maps” of critical pathways onto fluoroscopy and 3D maps. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa> Operators then concentrated radiofrequency energy on predicted isthmuses while sparing healthy tissue, aiming for safer, shorter, and more focused procedures. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Outcomes:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>VT noninducible at procedure end in all 10 patients (100% acute success). \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>No periprocedural complications reported. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Over ≈13‑month follow‑up, 8\u002F10 remained free of recurrent VT without antiarrhythmic drugs; 2 had early recurrences controllable with medication. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Historical recurrence rates near 40% after standard ablation make these outcomes encouraging, though direct comparative trials are lacking. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>💡 \u003Cstrong>Key takeaway:\u003C\u002Fstrong> In this feasibility study, every patient achieved acute VT suppression, and most remained arrhythmia‑free at one year without antiarrhythmic drugs. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003C\u002Fp>\n\u003Chr>\n\u003Ch2>Implications, Limitations, and the Future of Digital Heart Twins in Electrophysiology\u003C\u002Fh2>\n\u003Cp>Clinically, a 100% acute success rate and high arrhythmia‑free survival suggest that digital twin–guided ablation may:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Produce more targeted lesion sets\u003C\u002Fli>\n\u003Cli>Reduce unnecessary myocardial damage\u003C\u002Fli>\n\u003Cli>Potentially shorten procedure and fluoroscopy times\u003C\u002Fli>\n\u003Cli>Lower the need for repeat procedures and shocks in patients with implantable defibrillators \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-4\" class=\"citation-link\" title=\"View source [4]\">[4]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Digital twins also align with the broader vision of precision cardiology. Validated virtual organs can integrate structural imaging, ECG data, device telemetry, and eventually genomics to support individualized risk prediction and therapy planning. \u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003Ca href=\"#source-8\" class=\"citation-link\" title=\"View source [8]\">[8]\u003C\u002Fa> As new data are added, the twin could evolve with the patient, enabling dynamic forecasts of disease trajectory and treatment response. \u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Yet major caveats remain:\u003C\u002Fp>\n\u003Cul>\n\u003Cli>Only 10 patients, single‑center, no randomized control arm. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-5\" class=\"citation-link\" title=\"View source [5]\">[5]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Limited generalizability and no proof of superiority, cost‑effectiveness, or long‑term durability. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Need for high‑quality MRI, modeling expertise, and robust integration with mapping systems. \u003Ca href=\"#source-3\" class=\"citation-link\" title=\"View source [3]\">[3]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fli>\n\u003Cli>Regulatory requirements for verification, validation, and uncertainty quantification are still evolving. \u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003Ca href=\"#source-8\" class=\"citation-link\" title=\"View source [8]\">[8]\u003C\u002Fa>\u003C\u002Fli>\n\u003C\u002Ful>\n\u003Cp>Looking ahead, cardiac digital twins may extend beyond VT to atrial fibrillation, heart failure device optimization, and structural interventions such as valve repair. \u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003Ca href=\"#source-8\" class=\"citation-link\" title=\"View source [8]\">[8]\u003C\u002Fa> Combining mechanistic models with artificial intelligence could accelerate simulation and refine parameter estimation from routine clinical data, supporting longitudinal “lifelong” heart twins across a patient’s care journey. \u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003Ca href=\"#source-8\" class=\"citation-link\" title=\"View source [8]\">[8]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>⚠️ \u003Cstrong>Key point:\u003C\u002Fstrong> For now, digital twins should be viewed as an investigational adjunct, not a replacement for guideline‑directed care; clinical judgment remains central. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fp>\n\u003Chr>\n\u003Ch2>Conclusion: What TWIN‑VT Signals for Personalized VT Care\u003C\u002Fh2>\n\u003Cp>In the FDA‑approved TWIN‑VT feasibility trial, patient‑specific digital heart twins successfully guided ablation in 10 high‑risk patients with post‑infarct VT, achieving 100% acute noninducibility and encouraging one‑year arrhythmia‑free survival without antiarrhythmic drugs in most participants. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa> The study illustrates how mechanistic simulations can sharpen precision in electrophysiology while highlighting the need for larger trials to confirm benefit, durability, and value. \u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fp>\n\u003Cp>Clinicians, health‑system leaders, and researchers should follow forthcoming multicenter studies and consider structured pilot collaborations with modeling teams as evidence matures, integrating digital twins thoughtfully alongside established VT care pathways. \u003Ca href=\"#source-1\" class=\"citation-link\" title=\"View source [1]\">[1]\u003C\u002Fa>\u003Ca href=\"#source-2\" class=\"citation-link\" title=\"View source [2]\">[2]\u003C\u002Fa>\u003Ca href=\"#source-6\" class=\"citation-link\" title=\"View source [6]\">[6]\u003C\u002Fa>\u003Ca href=\"#source-7\" class=\"citation-link\" title=\"View source [7]\">[7]\u003C\u002Fa>\u003C\u002Fp>\n","From Ventricular Tachycardia to Digital Heart Twins: Why This Trial Matters\n\nVentricular tachycardia (VT) is a rapid rhythm from the heart’s lower chambers that can degenerate into ventricular fibrill...","trend-radar",[],1075,5,"2026-04-07T04:07:18.077Z",[17,22,26,30,33,37,41,45,49,53],{"title":18,"url":19,"summary":20,"type":21},"In a 10-patient feasibility study, heart digital twins were used to guide VT ablation. Afterward, VT was noninducible in all patients; at a mean follow-up of 13 months, 8 patients were free of recurrence, without drug therapy. Full study results: https:\u002F\u002Fnej.md\u002F4m20Xq0","https:\u002F\u002Fwww.threads.com\u002F@nejm\u002Fpost\u002FDWrOrU8kfmE\u002Fin-a-patient-feasibility-study-heart-digital-twins-were-used-to-guide-vt","In a 10-patient feasibility study, heart digital twins were used to guide VT ablation. Afterward, VT was noninducible in all patients; at a mean follow-up of 13 months, 8 patients were free of recurre...","kb",{"title":23,"url":24,"summary":25,"type":21},"Digital Twin–Guided Ablation for Ventricular Tachycardia","https:\u002F\u002Fepocrates.com\u002Fonline\u002Farticle\u002Fdigital-twin-heart-shows-promising-results-in-arrhythmia-ablation","Digital twin–guided ablation may improve targeting and outcomes in ventricular tachycardia, but evidence is limited to a small, single-center study.\n\nCatheter ablation for ventricular tachycardia can ...",{"title":27,"url":28,"summary":29,"type":21},"Digital twin hearts deliver 100% success in arrhythmia trial","https:\u002F\u002Fhub.jhu.edu\u002F2026\u002F04\u002F01\u002Fdigital-twin-hearts-arrhythmia-trial\u002F","By Jill Rosen\nPublished Apr 1\n\nWorking with \"digital twins\" of patients' hearts, doctors improved cardiac ablation outcomes for patients with life-threatening arrythmias.\n\nIn the first clinical trials...",{"title":27,"url":31,"summary":32,"type":21},"https:\u002F\u002Fwww.bme.jhu.edu\u002Fnews-events\u002Fnews\u002Fdigital-twin-hearts-deliver-100-success-in-arrhythmia-trial\u002F","April 2, 2026\n\nWorking with “digital twins” of patients’ hearts, doctors improved cardiac ablation outcomes for patients with life-threatening arrythmias.\n\nIn the first clinical trials for cardiac dig...",{"title":34,"url":35,"summary":36,"type":21},"To fix a patient’s irregular heartbeat, doctors first tested its digital ‘twin’","https:\u002F\u002Fwww.cnn.com\u002F2026\u002F04\u002F03\u002Fhealth\u002Fheart-health-digital-twin","Johns Hopkins University\u002FAP\n\nScientists created virtual replicas of patients’ diseased hearts so precise that blocking a dangerous irregular heartbeat in these digital “twins” showed doctors how to be...",{"title":38,"url":39,"summary":40,"type":21},"Digital heart replicas can guide a lifesaving procedure","https:\u002F\u002Fwww.sciencenews.org\u002Farticle\u002Fdigital-heart-replica-guide-ablation","By Elie Dolgin, April 1, 2026\n\nVirtual replicas of individual patients’ hearts have allowed doctors to refine and personalize a lifesaving medical procedure for dangerous rhythm disturbances.\n\nLike fl...",{"title":42,"url":43,"summary":44,"type":21},"Building Digital Twins for Cardiovascular Health: From Principles to Clinical Impact | Journal of the American Heart Association","https:\u002F\u002Fwww.ahajournals.org\u002Fdoi\u002F10.1161\u002FJAHA.123.031981","Abstract\n\nThe past several decades have seen rapid advances in diagnosis and treatment of cardiovascular diseases and stroke, enabled by technological breakthroughs in imaging, genomics, and physiolog...",{"title":46,"url":47,"summary":48,"type":21},"The ‘Digital Twin’ to enable the vision of precision cardiology _Open Access_","https:\u002F\u002Facademic.oup.com\u002Feurheartj\u002Farticle\u002F41\u002F48\u002F4556\u002F5775673","The ‘Digital Twin’ to enable the vision of precision cardiology Open Access\n\nJorge Corral-Acero, Jorge Corral-Acero\n\nDepartment of Engineering Science, University of Oxford, Oxford, UK\n\nSearch for oth...",{"title":50,"url":51,"summary":52,"type":21},"Cardiac Amyloidosis - Pipeline Insight, 2026","https:\u002F\u002Fwww.delveinsight.com\u002Freport-store\u002Fcardiac-amyloidosis-pipeline-insight","DelveInsight’s, \"Cardiac Amyloidosis- Pipeline Insight, 2026,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Cardiac Amyloidosis pipeline landscape. It covers th...",{"title":54,"url":55,"summary":56,"type":21},"Fasting-Mimicking Diet Beneficial in Mild-to-Moderate Crohn Disease - Gastroenterology Advisor","https:\u002F\u002Fwww.gastroenterologyadvisor.com\u002Fnews\u002Ffasting-mimicking-diet-beneficial-in-mild-to-moderate-crohn-disease\u002F","HealthDay News — A fasting-mimicking diet (FMD) is beneficial for induction of clinical response and clinical remission in patients with mild-to-moderate Crohn disease (CD), according to a study publi...",{"totalSources":58},10,{"generationDuration":60,"kbQueriesCount":58,"confidenceScore":61,"sourcesCount":58},134694,100,{"metaTitle":63,"metaDescription":64},"Digital Heart Twins Guide VT Ablation: 10-Patient Trial","See how Digital Heart Twins improved VT ablation in 10 patients—methods, outcomes and why it matters. Read to discover the trial's clinical impact.","en","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1739185253617-4fdc1cd3d62a?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxkaWdpdGFsJTIwaGVhcnQlMjB0d2lucyUyMGd1aWRlZHxlbnwxfDB8fHwxNzc1NTM0Mzc1fDA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60",{"photographerName":68,"photographerUrl":69,"unsplashUrl":70},"Marek Studzinski","https:\u002F\u002Funsplash.com\u002F@jccards?utm_source=coreprose&utm_medium=referral","https:\u002F\u002Funsplash.com\u002Fphotos\u002Fa-picture-of-a-heart-on-a-screen-i6R2xkq29lY?utm_source=coreprose&utm_medium=referral",true,{"key":73,"name":74,"nameEn":75},"sante","Santé & Médecine","Health & Medicine",[77,79,81,83],{"text":78},"The FDA‑approved TWIN‑VT feasibility trial used MRI‑based digital heart twins to guide VT ablation in 10 post‑infarct patients and achieved 100% acute noninducibility at procedure end.",{"text":80},"Eight of 10 patients (80%) remained free of recurrent VT without antiarrhythmic drugs over ≈13 months of follow‑up; two had early recurrences that were controlled with medication.",{"text":82},"No periprocedural complications were reported, and model‑derived targets were integrated with clinical mapping systems to focus lesions on predicted isthmuses and spare healthy myocardium.",{"text":84},"The study is single‑center, nonrandomized, and limited to patients with high‑quality contrast MRI; larger randomized trials are required to prove superiority, cost‑effectiveness, and long‑term durability.",[86,89,92],{"question":87,"answer":88},"What exactly did the TWIN‑VT trial demonstrate?","TWIN‑VT demonstrated that individualized, MRI‑based digital heart twins can prospectively guide VT ablation planning: in 10 high‑risk post‑infarct patients the approach produced 100% acute VT noninducibility and an 80% arrhythmia‑free rate off antiarrhythmic drugs at about 13 months, with no reported periprocedural complications. The workflow reconstructed 3D ventricular anatomy, assigned tissue‑specific electrical properties, provoked re‑entrant VTs in silico, and iteratively tested virtual lesion sets until simulated VT suppression; those model‑derived targets were then overlaid onto clinical mapping systems to concentrate ablation on predicted critical isthmuses. While outcomes are encouraging, the trial’s single‑center, nonrandomized design and small sample size prevent definitive claims of superiority over conventional ablation and require validation in larger controlled studies.",{"question":90,"answer":91},"Who are the best candidates for digital twin–guided VT ablation?","Ideal candidates are patients with post‑infarct, scar‑related VT who can undergo high‑quality contrast‑enhanced cardiac MRI and who have recurrent, drug‑refractory arrhythmias or high risk for recurrence after conventional ablation. The technique relies on clear scar delineation and border‑zone characterization from MRI plus integration with electrophysiology mapping systems, so patients with contraindications to MRI or poor image quality are less suitable. Clinical teams should also have access to modeling expertise and workflow integration resources before selecting patients for this investigational approach.",{"question":93,"answer":94},"What are the main limitations and next steps for digital heart twins in VT care?","The main limitations are small sample size (10 patients), single‑center design, lack of a randomized control arm, need for high‑quality MRI and specialized modeling expertise, and unresolved questions about cost‑effectiveness and long‑term durability. Next steps include multicenter randomized trials comparing twin‑guided versus conventional ablation, standardizing validation and uncertainty quantification processes, improving automation and speed of simulations, and evaluating scalability, reimbursement models, and outcomes across broader patient populations.",[96,102,107,111,116,121,125,130,135,139,144,149,154,159,163],{"id":97,"name":98,"type":99,"confidence":100,"wikipediaUrl":101},"69d483194eea09eba3e02f9a","Digital heart twin","concept",0.98,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FList_of_Twin_Peaks_episodes",{"id":103,"name":104,"type":99,"confidence":105,"wikipediaUrl":106},"69d483184eea09eba3e02f93","Ventricular fibrillation",0.95,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FVentricular_fibrillation",{"id":108,"name":109,"type":99,"confidence":100,"wikipediaUrl":110},"69d483184eea09eba3e02f92","Ventricular tachycardia","https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FVentricular_tachycardia",{"id":112,"name":113,"type":99,"confidence":114,"wikipediaUrl":115},"69d483194eea09eba3e02f99","Medical digital twin",0.97,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FDigital_twin",{"id":117,"name":118,"type":99,"confidence":119,"wikipediaUrl":120},"69d4831a4eea09eba3e02fa2","Antiarrhythmic drugs",0.92,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FAntiarrhythmic_agent",{"id":122,"name":123,"type":99,"confidence":114,"wikipediaUrl":124},"69d483194eea09eba3e02f95","Myocardial infarction","https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FMyocardial_infarction",{"id":126,"name":127,"type":99,"confidence":128,"wikipediaUrl":129},"69d483194eea09eba3e02f96","Scar tissue",0.93,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FScar_Tissue",{"id":131,"name":132,"type":99,"confidence":133,"wikipediaUrl":134},"69d4831b4eea09eba3e02fa4","Artificial intelligence",0.88,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FArtificial_intelligence",{"id":136,"name":137,"type":99,"confidence":100,"wikipediaUrl":138},"69d483194eea09eba3e02f97","Catheter ablation","https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FCatheter_ablation",{"id":140,"name":141,"type":99,"confidence":142,"wikipediaUrl":143},"69d4831a4eea09eba3e02f9f","In-silico testing",0.94,null,{"id":145,"name":146,"type":99,"confidence":147,"wikipediaUrl":148},"69d483194eea09eba3e02f94","Sudden cardiac arrest",0.96,"https:\u002F\u002Fen.wikipedia.org\u002Fwiki\u002FCardiac_arrest",{"id":150,"name":151,"type":152,"confidence":153,"wikipediaUrl":143},"69d4831a4eea09eba3e02f9c","TWIN-VT trial","event",0.99,{"id":155,"name":156,"type":157,"confidence":158,"wikipediaUrl":143},"69d4831a4eea09eba3e02f9e","Electrophysiology lab","location",0.85,{"id":160,"name":161,"type":162,"confidence":100,"wikipediaUrl":143},"69d4831a4eea09eba3e02f9d","FDA","organization",{"id":164,"name":165,"type":166,"confidence":114,"wikipediaUrl":143},"69d4831a4eea09eba3e02fa1","Procedure outcomes (TWIN-VT)","other",[168],{"id":169,"title":170,"slug":171,"excerpt":172,"category":11,"featuredImage":173,"publishedAt":174},"69d245a2b3b92dfc3f9f296a","Five-Day Fasting-Mimicking Diet Shows Promise for Crohn’s Disease Relief","five-day-fasting-mimicking-diet-shows-promise-for-crohn-s-disease-relief","For many people with Crohn’s disease, diet feels like a missing treatment piece. A new Stanford-led randomized clinical trial suggests a structured, five-day‑a‑month fasting-mimicking diet (FMD) can i...","https:\u002F\u002Fimages.unsplash.com\u002Fphoto-1767972159709-52936afffdbf?ixid=M3w4OTczNDl8MHwxfHNlYXJjaHwxfHxmaXZlJTIwZGF5JTIwZmFzdGluZyUyMG1pbWlja2luZ3xlbnwxfDB8fHwxNzc1MzQxMzMwfDA&ixlib=rb-4.1.0&w=1200&h=630&fit=crop&crop=entropy&auto=format,compress&q=60","2026-04-05T11:26:13.402Z",["Island",176],{"key":177,"params":178,"result":180},"ArticleBody_eBxDhLXKU2ANyBIfEPFTZGE1dTKn627MgMjsD3jO7VA",{"props":179},"{\"articleId\":\"69d48127fc9a83011893c2c3\"}",{"head":181},{}]